Comparative insights into Fusobacterium nucleatum and Helicobacter pylori in human cancers

2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3389/fmicb.2025.1677795
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Fusobacterium nucleatum and Helicobacter pylori are two microbial species increasingly recognized for their roles in gastrointestinal (GI) carcinogenesis, particularly in colorectal cancer (CRC) and gastric cancer (GC), respectively. While H. pylori has been long classified as a Group 1 carcinogen due to its well-characterized pathogenic mechanisms, F. nucleatum has more recently emerged as a key microbial contributor to CRC, with growing evidence linking it to tumor progression, immune evasion, and poor clinical outcomes. Despite occupying anatomically distinct niches within the GI tract, both bacteria converge on similar oncogenic pathways, including the activation of NF-κB signaling, β-catenin pathway dysregulation, and epithelial barrier disruption. In parallel, dietary factors – particularly the consumption of red and processed meats – contribute additional oncogenic pressure via carcinogenic compounds such as heme iron, N-nitroso compounds, and polycyclic aromatic hydrocarbons. These dietary components not only damage host tissue but may also potentiate bacterial virulence and promote microbial persistence. This review provides a comparative analysis of the oncogenic strategies employed by F. nucleatum and H. pylori , with an emphasis on their interactions with diet-derived carcinogens and implications for therapeutic interventions targeting the microbiota–diet–host axis in GI cancers.